Bristol-Myers Squibb (BMY) Shares Pop as Ipilimumab Reaches Primary Endpoint
- Wall Street ends sharply higher, fueled by Apple
- Here's Which Stocks Warren Buffett's Berkshire (BRK) Bought in Q1
- Walmart (WMT) Stock Drops 6% as Higher Costs Weigh on Profit, Analyst Says Results 'Disappointing'
- Home Depot (HD) Shares Rally 4% on Earnings Beat, Results Seen as Strong
- Bear Rally Now 'Imminent' Says BofA's Hartnett but Warns Ultimate Lows Yet to Be Reached
Bristol-Myers Squibb (NYSE: BMY) shares are popping after-hours today following an announcement that ipilimumab clinical trial met the primary endpoint of improving overall survival in previously-untreated patients with metastatic melanoma. Shares are up 4.9% post-market.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bristol-Myers Squibb Co. (BMY) PT Raised to $70 at Wells Fargo
- Bristol-Myers Squibb (BMY) Sells Manufacturing Facility in East Syracuse, New York to LOTTE
- Here's Which 3 Tech Stocks Hedge Funds Were Selling the Most in Q1
Create E-mail Alert Related CategoriesFDA, Insiders' Blog, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!